Cellectar Biosciences Inc
CLRB
Get informed when a big investor buys or sells
+ FollowMarket Cap$20.77M
Close$
$4.90
97.7% upside
Current Fair Value
97.7% upsideUndervalued by 97.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $20.77 Million |
|---|---|
| Enterprise Value | $-11,688,410.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-8.35 |
| Beta | 0.55 |
| Outstanding Shares | 12,231,851 |
Return
| Return on Equity | -74.73% |
|---|---|
| Return on Assets | -60.93% |
| Return on Invested Capital | -74.26% |
Valuation & Multiples
| P/E Ratio | -0.57 |
|---|---|
| PEG | -2.09 |
| Price to Sales | - |
| Price to Book Ratio | 1.24 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.5 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.13 |
| Debt to Equity | 0.05 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-0.52
Average shareholder expectationRevenue Estimate
$12.00 M
Average shareholder expectationNext Earnings Call
Expected Date
August 19, 2026
EPS Estimate
$-0.59
Average shareholder expectationRevenue Estimate
$12.00 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 7.33%▼ 0.85% |
|---|---|
| Total Invested | $812,903▼ 22.03% |
| Investors Holding | 19▼ 1.00% |
ESG Score
No data
About Cellectar Biosciences Inc
CEO: James Caruso